WGU D116 ADVANCED PHARMACOLOGY FINAL EXAM
– COMPREHENSIVE PRACTICE ASSESSMENT - ACTUAL
EXAM PRACTICE QUESTIONS AND 100% VERIFIED
CORRECT ANSWERS | COMPLETE EXAM PREP
TESTBANK | GUARANTEED PASS | INSTANT
DOWNLOAD PDF
Core Domains
1. Pharmacokinetics and Pharmacodynamics
2. Autonomic Nervous System Pharmacology
3. Cardiovascular and Renal Pharmacology
4. Endocrine and Metabolic Pharmacology
5. Central Nervous System Pharmacology
6. Anti-Infective Pharmacology
7. Pain Management and Anti-Inflammatory Pharmacology
8. Drug Safety, Toxicology, and Adverse Drug Reactions
9. Pharmacology Ethics, Regulations, and Prescribing Principles
,Table of Contents
Section Title Page
1 Introduction 1
2 Pharmacokinetics and Pharmacodynamics 2
3 Autonomic Nervous System Pharmacology 4
4 Cardiovascular and Renal Pharmacology 6
5 Endocrine and Metabolic Pharmacology 8
6 Central Nervous System Pharmacology 10
7 Anti-Infective Pharmacology 12
8 Pain Management and Anti-Inflammatory Pharmacology 14
9 Drug Safety, Toxicology, and Adverse Reactions 16
10 Ethics, Regulations, and Prescribing Standards 18
11 Answer Key Summary 20
Introduction
The WGU D116 Advanced Pharmacology Final Exam evaluates the learner’s
ability to apply pharmacologic knowledge in clinical decision-making. The
assessment emphasizes pharmacokinetics, pharmacodynamics, therapeutic drug
classes, adverse reactions, drug interactions, and evidence-based prescribing
practices. Questions are designed to test theoretical knowledge, applied
pharmacology, patient-safety considerations, and clinical reasoning across multiple
body systems. The exam uses multiple-choice questions including clinical
scenarios, patient-case analysis, and drug-therapy problem solving. Candidates are
expected to demonstrate competency in medication selection, monitoring, patient
education, and regulatory compliance while maintaining professional and ethical
prescribing practices.
,Section 1 (Questions 1–35)
1. A drug that binds to receptors and produces maximal biological response is
known as:
A. Competitive antagonist
B. Partial agonist
C. Full agonist
D. Inverse agonist
Rationale: A full agonist binds and activates receptors to produce the maximal
physiological response.
2. Which pharmacokinetic phase involves enzymatic alteration of a drug
primarily in the liver?
A. Absorption
B. Distribution
C. Metabolism
D. Elimination
Rationale: Drug metabolism occurs primarily in the liver through enzyme systems
such as cytochrome P450.
3. A patient taking warfarin begins therapy with trimethoprim-
sulfamethoxazole and develops bleeding. This interaction most likely results
from:
A. Increased renal clearance of warfarin
B. Reduced protein binding of antibiotic
C. Inhibition of warfarin metabolism
D. Increased vitamin K production
Rationale: Sulfonamides inhibit hepatic metabolism of warfarin, increasing
anticoagulant effect.
, 4. The therapeutic index of a medication represents:
A. Bioavailability of the drug
B. Duration of drug action
C. Ratio of toxic dose to effective dose
D. Percentage bound to plasma proteins
Rationale: Therapeutic index reflects safety margin between effective and toxic
doses.
5. Which route of administration bypasses first-pass hepatic metabolism?
A. Oral
B. Sublingual
C. Gastric tube
D. Rectal
Rationale: Sublingual medications enter systemic circulation directly.
6. A beta-1 selective blocker commonly prescribed for hypertension is:
A. Propranolol
B. Nadolol
C. Metoprolol
D. Timolol
Rationale: Metoprolol selectively blocks β1 receptors affecting heart rate and
contractility.
7. Which adverse effect is most commonly associated with ACE inhibitors?
A. Bradycardia
B. Hyperglycemia
– COMPREHENSIVE PRACTICE ASSESSMENT - ACTUAL
EXAM PRACTICE QUESTIONS AND 100% VERIFIED
CORRECT ANSWERS | COMPLETE EXAM PREP
TESTBANK | GUARANTEED PASS | INSTANT
DOWNLOAD PDF
Core Domains
1. Pharmacokinetics and Pharmacodynamics
2. Autonomic Nervous System Pharmacology
3. Cardiovascular and Renal Pharmacology
4. Endocrine and Metabolic Pharmacology
5. Central Nervous System Pharmacology
6. Anti-Infective Pharmacology
7. Pain Management and Anti-Inflammatory Pharmacology
8. Drug Safety, Toxicology, and Adverse Drug Reactions
9. Pharmacology Ethics, Regulations, and Prescribing Principles
,Table of Contents
Section Title Page
1 Introduction 1
2 Pharmacokinetics and Pharmacodynamics 2
3 Autonomic Nervous System Pharmacology 4
4 Cardiovascular and Renal Pharmacology 6
5 Endocrine and Metabolic Pharmacology 8
6 Central Nervous System Pharmacology 10
7 Anti-Infective Pharmacology 12
8 Pain Management and Anti-Inflammatory Pharmacology 14
9 Drug Safety, Toxicology, and Adverse Reactions 16
10 Ethics, Regulations, and Prescribing Standards 18
11 Answer Key Summary 20
Introduction
The WGU D116 Advanced Pharmacology Final Exam evaluates the learner’s
ability to apply pharmacologic knowledge in clinical decision-making. The
assessment emphasizes pharmacokinetics, pharmacodynamics, therapeutic drug
classes, adverse reactions, drug interactions, and evidence-based prescribing
practices. Questions are designed to test theoretical knowledge, applied
pharmacology, patient-safety considerations, and clinical reasoning across multiple
body systems. The exam uses multiple-choice questions including clinical
scenarios, patient-case analysis, and drug-therapy problem solving. Candidates are
expected to demonstrate competency in medication selection, monitoring, patient
education, and regulatory compliance while maintaining professional and ethical
prescribing practices.
,Section 1 (Questions 1–35)
1. A drug that binds to receptors and produces maximal biological response is
known as:
A. Competitive antagonist
B. Partial agonist
C. Full agonist
D. Inverse agonist
Rationale: A full agonist binds and activates receptors to produce the maximal
physiological response.
2. Which pharmacokinetic phase involves enzymatic alteration of a drug
primarily in the liver?
A. Absorption
B. Distribution
C. Metabolism
D. Elimination
Rationale: Drug metabolism occurs primarily in the liver through enzyme systems
such as cytochrome P450.
3. A patient taking warfarin begins therapy with trimethoprim-
sulfamethoxazole and develops bleeding. This interaction most likely results
from:
A. Increased renal clearance of warfarin
B. Reduced protein binding of antibiotic
C. Inhibition of warfarin metabolism
D. Increased vitamin K production
Rationale: Sulfonamides inhibit hepatic metabolism of warfarin, increasing
anticoagulant effect.
, 4. The therapeutic index of a medication represents:
A. Bioavailability of the drug
B. Duration of drug action
C. Ratio of toxic dose to effective dose
D. Percentage bound to plasma proteins
Rationale: Therapeutic index reflects safety margin between effective and toxic
doses.
5. Which route of administration bypasses first-pass hepatic metabolism?
A. Oral
B. Sublingual
C. Gastric tube
D. Rectal
Rationale: Sublingual medications enter systemic circulation directly.
6. A beta-1 selective blocker commonly prescribed for hypertension is:
A. Propranolol
B. Nadolol
C. Metoprolol
D. Timolol
Rationale: Metoprolol selectively blocks β1 receptors affecting heart rate and
contractility.
7. Which adverse effect is most commonly associated with ACE inhibitors?
A. Bradycardia
B. Hyperglycemia
